Table 4 Different MSC-EXOs in a clinical trial
MSCs-EXOs | Diseases | Clinical study stage | Participants | Injection route | Ref | Trial aim |
|---|---|---|---|---|---|---|
MSC-EXOs (SY) | Pancreatic Cancer | Phase 1 | 28 | Intravenously | NCT03608631 [150] | Mesenchymal stromal cells-derived exosomes with KRAS G12D siRNA |
AD-MSCs-EXOs | COVID-19 | Phase 1 | 24 | Aerosol inhalation | NCT04276987 [151] | A pilot clinical study on inhalation of mesenchymal stem cells exosomes treating severe novel coronavirus pneumonia |
MSC-EXOs | COVID-19 | Phase 1 Phase 2 | 30 | Inhalation | NCT04276987 [176] | Evaluation of safety and efficiency of method of exosome inhalation in SARS-CoV-2 associated pneumonia |
Allogenic AD-MSCs-EXOs | Alzheimer disease | Phase 1 Phase 2 | 9 | Inhalation (Nasal drip) | NCT04388982 [177] | the Safety and the Efficacy Evaluation of Allogenic Adipose MSC-Exos in Patients with Alzheimer's disease |
UC-MSCs-EXOs | Macular holes (MHs) | Early Phase 1 | 44 | Intravitreal injection | NCT03437759 [178] | Promoting healing of large and refractory macular holes (MHs) |
Dermama-MSCs-EXOs | COVID-19 | Phase 2 Phase 3 | 60 | Intravenous route | NCT05216562 | Efficacy and safety of EXOSOME-MSC (mesenchymal stem cell-derived exosomes) therapy to reduce hyper-inflammation in moderate COVID-19 |
WJ-MSCs-EXOs | Retinitis Pigmentosa | Phase 2 Phase 3 | 135 | Subtenon injection | NCT05413148 [179] | The effect of stem cells and stem cell exosomes on visual functions in patients with retinitis pigmentosa |
UC-MSCs-EXOs | Diabetes Mellitus Type 1 | Phase 2 Phase 3 | 20 | Intravenous | NCT02138331 [180] | Effect of microvesicles and exosomes therapy on β-cell Mass in Type I diabetes mellitus (T1DM) |